Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
Public ClinicalTrials.gov record NCT05138133. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre Randomized Double-Blind Placebo Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Study identification
- NCT ID
- NCT05138133
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 363 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 15, 2022 (Actual)
- Primary completion
- Feb 23, 2027 (Estimated)
- Completion
- Oct 4, 2028 (Estimated)
- Last update posted
- Jul 31, 2026
2022 – 2028
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Glendale | Arizona | 85306 | — |
| Research Site | La Palma | California | 90623 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Upland | California | 91786 | — |
| Research Site | Plantation | Florida | 33324 | — |
| Research Site | Atlanta | Georgia | 30308 | — |
| Research Site | Louisville | Kentucky | 40202 | — |
| Research Site | Summit | New Jersey | 07901 | — |
| Research Site | Manhasset | New York | 11030 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Winston-Salem | North Carolina | 27157 | — |
| Research Site | Middleburg Heights | Ohio | 44130 | — |
| Research Site | Colleyville | Texas | 76034 | — |
| Research Site | Edinburg | Texas | 78539 | — |
| Research Site | El Paso | Texas | 79902 | — |
| Research Site | Houston | Texas | 77054 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 148 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05138133, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2026 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05138133 live on ClinicalTrials.gov.